25Indexed trials
drug · Product Intelligence
LEVETIRACETAM
Pipeline Intelligence
LEVETIRACETAM: 25 indexed trials, 14 sponsors; 1 linked Orange Book patents and 13 FDA-linked events where matched.
14Sponsors
1Orange Book patent links
13FDA-linked events
Development evidence
NCT00150709UCB Pharma · epilepsyPHASE3
NCT00150735UCB Pharma · epilepsyPHASE3
NCT00150787UCB Pharma · epilepsyPHASE3
NCT00152373UCB Pharma · epilepsyPHASE3
NCT00160654UCB Pharma · epilepsyPHASE4
NCT00319605UCB Pharma · epilepsyCOMPLETED
NCT00361010The Cleveland Clinic · epilepsyNA
NCT00367432UCB Japan Co. Ltd. · epilepsyPHASE3
NCT00370838Harvey S. Singer · neurodevelopmental_otherPHASE4
NCT00423527Odense University Hospital · multiple_sclerosisPHASE4
NCT00535392UCB Pharma · epilepsyPHASE2
NCT00545012UCB Pharma · epilepsyPHASE2
NCT00615615UCB Pharma · epilepsyPHASE3
NCT00630630UCB Pharma · epilepsyPHASE4
NCT01228747UCB Japan Co. Ltd. · epilepsyPHASE3
FDA / patent evidence
7858122KEPPRA XR · app 0222852028-09-17
Regulatory context
FDA_APPROVALLEVETIRACETAM · 2022-10-07
FDA_APPROVALLEVETIRACETAM · 2022-07-15
FDA_APPROVALLEVETIRACETAM · 2017-09-28
FDA_APPROVALLEVETIRACETAM · 2016-06-06
FDA_APPROVALLEVETIRACETAM · 2015-05-21
FDA_APPROVALLEVETIRACETAM · 2012-07-20
FDA_APPROVALLEVETIRACETAM · 2012-02-28
FDA_APPROVALLEVETIRACETAM · 2011-09-12
FDA_APPROVALLEVETIRACETAM · 2011-06-14
FDA_APPROVALLEVETIRACETAM · 2010-03-03
FDA_APPROVALKEPPRA XR · 2009-02-12
FDA_APPROVALLEVETIRACETAM · 2009-01-16
FDA Orange Book coverage is U.S.-specific and is not a substitute for worldwide patent or regulatory review.